10-Q Filing

BEONE MEDICINES LTD. CIK: 1651308 Q1 2020

Filing Information

Form Type	10-Q
Accession Number	`0001651308-20-000056`
Period End Date	20200331
Filing Date	20200511
Fiscal Year	2020
Fiscal Period	Q1
XBRL Instance	beigene2020q110-q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 91 Income Statement 36 Cash Flow Statement 93 Stockholders Equity 21 Comprehensive Income 12

Balance Sheet 91 line items

Line Item	Tag	Value	Unit	Period
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$764.49M	USD	Point-in-time
Ordinary shares, shares authorized (in shares)	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Ordinary shares, shares authorized (in shares)	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.96B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$618.01M	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$288.00K	USD	Point-in-time
Ordinary shares, shares issued (in shares)	`CommonStockSharesIssued`	801.34M	shares	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$282.00K	USD	Point-in-time
Ordinary shares, shares issued (in shares)	`CommonStockSharesIssued`	1.01B	shares	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$14.90M	USD	Point-in-time
Short-term investments	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$364.73M	USD	Point-in-time
Short-term investments	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$1.42B	USD	Point-in-time
Ordinary shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	1.01B	shares	Point-in-time
Ordinary shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	801.34M	shares	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$65.62M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$70.88M	USD	Point-in-time
Inventories	`InventoryNet`	$28.55M	USD	Point-in-time
Inventories	`InventoryNet`	$28.77M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$126.31M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$90.24M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.60B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.17B	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$8.99M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$2.48M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$2.44M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$242.40M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$240.33M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$82.52M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$91.51M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$5.85M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$5.56M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$37.94M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$37.89M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$94.25M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$68.45M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$472.02M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$439.59M	USD	Point-in-time
Total assets	`Assets`	$4.07B	USD	Point-in-time
Total assets	`Assets`	$1.61B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$98.36M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$122.49M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesCurrent`	$179.33M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesCurrent`	$163.56M	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$13.45M	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$19.54M	USD	Point-in-time
Operating lease liabilities, current portion	`OperatingLeaseLiabilityCurrent`	$14.60M	USD	Point-in-time
Operating lease liabilities, current portion	`OperatingLeaseLiabilityCurrent`	$10.81M	USD	Point-in-time
Research and development cost share liability, current portion	`ResearchAndDevelopmentCostShareLiabilityCurrentPortion`	-	USD	Point-in-time
Research and development cost share liability, current portion	`ResearchAndDevelopmentCostShareLiabilityCurrentPortion`	$128.67M	USD	Point-in-time
Short-term bank loan	`LongTermDebtCurrent`	$11.30M	USD	Point-in-time
Short-term bank loan	`LongTermDebtCurrent`	-	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$451.80M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$310.31M	USD	Point-in-time
Long-term bank loan	`LongTermDebtNoncurrent`	$83.31M	USD	Point-in-time
Long-term bank loan	`LongTermDebtNoncurrent`	$81.91M	USD	Point-in-time
Shareholder loan	`DueToRelatedPartiesNoncurrent`	$157.38M	USD	Point-in-time
Shareholder loan	`DueToRelatedPartiesNoncurrent`	$157.28M	USD	Point-in-time
Operating lease liabilities, non-current portion	`OperatingLeaseLiabilityNoncurrent`	$32.97M	USD	Point-in-time
Operating lease liabilities, non-current portion	`OperatingLeaseLiabilityNoncurrent`	$25.83M	USD	Point-in-time
Deferred tax liabilities	`DeferredIncomeTaxLiabilitiesNet`	$10.37M	USD	Point-in-time
Deferred tax liabilities	`DeferredIncomeTaxLiabilitiesNet`	$10.53M	USD	Point-in-time
Research and development cost share liability, non-current portion	`ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion`	$460.53M	USD	Point-in-time
Research and development cost share liability, non-current portion	`ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion`	-	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$45.30M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$46.56M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$323.62M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$788.36M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.24B	USD	Point-in-time
Total liabilities	`Liabilities`	$633.93M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Ordinary shares, US$0.0001 par value per share; 9,500,000,000 shares authorized; 1,007,976,816 and 801,340,698 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	`CommonStockValue`	$79.00K	USD	Point-in-time
Ordinary shares, US$0.0001 par value per share; 9,500,000,000 shares authorized; 1,007,976,816 and 801,340,698 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	`CommonStockValue`	$101.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$2.93B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$5.14B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-8.00M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-6.55M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.96B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-2.32B	USD	Point-in-time
Total BeiGene, Ltd. shareholders equity	`StockholdersEquity`	$2.81B	USD	Point-in-time
Total BeiGene, Ltd. shareholders equity	`StockholdersEquity`	$962.21M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$16.15M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$14.84M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.62B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$978.36M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.83B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$4.07B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$1.61B	USD	Point-in-time

Income Statement 36 line items

Line Item	Tag	Value	Unit	Period
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$52.06M	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$77.83M	USD	1 Quarter
Cost of sales - product	`CostOfGoodsAndServicesSold`	$14.15M	USD	1 Quarter
Cost of sales - product	`CostOfGoodsAndServicesSold`	$15.26M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$304.30M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$178.35M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$57.65M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$107.08M	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$331.00K	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$283.00K	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$425.81M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$251.59M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-173.75M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-373.76M	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$4.48M	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$6.69M	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$3.68M	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$1.73M	USD	1 Quarter
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-167.55M	USD	1 Quarter
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-363.38M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$1.55M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$519.00K	USD	1 Quarter
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-429.00K	USD	1 Quarter
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-1.20M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-363.74M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-167.64M	USD	1 Quarter
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.22	USD	1 Quarter
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.36	USD	1 Quarter
Weighted-average shares outstanding, basic and diluted (shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	774.75M	shares	1 Quarter
Weighted-average shares outstanding, basic and diluted (shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	1.01B	shares	1 Quarter
Net loss per American Depositary Share (ADS), basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-4.70	USD	1 Quarter
Net loss per American Depositary Share (ADS), basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-2.81	USD	1 Quarter
Weighted-average ADSs outstanding, basic and diluted (shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstanding`	77.33M	shares	1 Quarter
Weighted-average ADSs outstanding, basic and diluted (shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstanding`	59.60M	shares	1 Quarter

Cash Flow Statement 93 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$7.75M	USD	1 Quarter
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$3.42M	USD	1 Quarter
Share-based compensation expenses	`ShareBasedCompensation`	$38.26M	USD	1 Quarter
Share-based compensation expenses	`ShareBasedCompensation`	$26.39M	USD	1 Quarter
Provision for doubtful accounts	`ProvisionForDoubtfulAccounts`	$2.02M	USD	1 Quarter
Provision for doubtful accounts	`ProvisionForDoubtfulAccounts`	-	USD	1 Quarter
Unrealized gain on equity securities	`UnrealizedGainLossOnInvestments`	$6.96M	USD	1 Quarter
Unrealized gain on equity securities	`UnrealizedGainLossOnInvestments`	-	USD	1 Quarter
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$29.00M	USD	1 Quarter
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$43.00M	USD	1 Quarter
Amortization of research and development cost share liability	`AmortizationofResearchAndDevelopmentFinancingLiability`	$-27.63M	USD	1 Quarter
Amortization of research and development cost share liability	`AmortizationofResearchAndDevelopmentFinancingLiability`	-	USD	1 Quarter
Non-cash interest expense	`InterestExpenseOperatingActivities`	$1.86M	USD	1 Quarter
Non-cash interest expense	`InterestExpenseOperatingActivities`	$2.57M	USD	1 Quarter
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-983.00K	USD	1 Quarter
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-206.00K	USD	1 Quarter
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$-3.22M	USD	1 Quarter
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$-1.10M	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$17.92M	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-3.24M	USD	1 Quarter
Inventories	`IncreaseDecreaseInInventories`	$-3.10M	USD	1 Quarter
Inventories	`IncreaseDecreaseInInventories`	$222.00K	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$5.77M	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$36.08M	USD	1 Quarter
Operating lease right-of-use assets	`IncreaseDecreaseInOperatingLeaseRightofUseAsset`	$1.59M	USD	1 Quarter
Operating lease right-of-use assets	`IncreaseDecreaseInOperatingLeaseRightofUseAsset`	$8.99M	USD	1 Quarter
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$10.21M	USD	1 Quarter
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$2.71M	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-20.36M	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-21.45M	USD	1 Quarter
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$-8.79M	USD	1 Quarter
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$15.78M	USD	1 Quarter
Tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$6.08M	USD	1 Quarter
Tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$969.00K	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-2.24M	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	-	USD	1 Quarter
Operating lease liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$10.92M	USD	1 Quarter
Operating lease liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$1.55M	USD	1 Quarter
Other long-term liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-1.26M	USD	1 Quarter
Other long-term liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$892.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-171.97M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-341.94M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$21.83M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$21.53M	USD	1 Quarter
Purchases of investments	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$487.35M	USD	1 Quarter
Purchases of investments	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$1.31B	USD	1 Quarter
Proceeds from sale or maturity of investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$256.74M	USD	1 Quarter
Proceeds from sale or maturity of investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$710.60M	USD	1 Quarter
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$43.00M	USD	1 Quarter
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$29.00M	USD	1 Quarter
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$172.42M	USD	1 Quarter
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.11B	USD	1 Quarter
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStockNetOfUnderwriterDiscount`	-	USD	1 Quarter
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStockNetOfUnderwriterDiscount`	$2.16B	USD	1 Quarter
Proceeds from research and development cost share liability	`ProceedsFromResearchAndDevelopmentFinancingLiability`	-	USD	1 Quarter
Proceeds from research and development cost share liability	`ProceedsFromResearchAndDevelopmentFinancingLiability`	$616.83M	USD	1 Quarter
Proceeds from long-term bank loan	`ProceedsFromLongTermLinesOfCredit`	$36.70M	USD	1 Quarter
Proceeds from long-term bank loan	`ProceedsFromLongTermLinesOfCredit`	-	USD	1 Quarter
Proceeds from short-term bank loan	`ProceedsFromShortTermDebt`	$11.30M	USD	1 Quarter
Proceeds from short-term bank loan	`ProceedsFromShortTermDebt`	-	USD	1 Quarter
Proceeds from option exercises and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$6.27M	USD	1 Quarter
Proceeds from option exercises and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$11.63M	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.80B	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$42.96M	USD	1 Quarter
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-6.21M	USD	1 Quarter
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$4.26M	USD	1 Quarter
Net increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$47.67M	USD	1 Quarter
Net increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.34B	USD	1 Quarter
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.96B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$740.71M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$788.38M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$620.77M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.96B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$740.71M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$788.38M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$620.77M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$764.49M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.96B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$618.01M	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$288.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$282.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$14.90M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$8.99M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$2.48M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$2.44M	USD	Point-in-time
Income taxes paid	`IncomeTaxesPaidNet`	$531.00K	USD	1 Quarter
Income taxes paid	`IncomeTaxesPaidNet`	$360.00K	USD	1 Quarter
Interest paid	`InterestPaidNet`	$1.14M	USD	1 Quarter
Interest paid	`InterestPaidNet`	$888.00K	USD	1 Quarter
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$32.46M	USD	1 Quarter
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$26.41M	USD	1 Quarter

Stockholders Equity 21 line items

Line Item	Tag	Value	Unit	Period
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.62B	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$978.36M	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.83B	USD	Point-in-time
Balance at the beginning of period (in shares)	`CommonStockSharesOutstanding`	1.01B	shares	Point-in-time
Balance at the beginning of period (in shares)	`CommonStockSharesOutstanding`	801.34M	shares	Point-in-time
Issuance of ordinary shares in connection with collaboration	`StockIssuedDuringPeriodValueNewIssues`	$2.16B	USD	1 Quarter
Exercise of options, ESPP and release of Restricted Share Units (RSUs)	`StockIssuedDuringPeriodValueStockOptionsExercised`	$11.63M	USD	1 Quarter
Exercise of options, ESPP and release of Restricted Share Units (RSUs)	`StockIssuedDuringPeriodValueStockOptionsExercised`	$6.27M	USD	1 Quarter
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$38.26M	USD	1 Quarter
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$26.39M	USD	1 Quarter
Other comprehensive income	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$4.44M	USD	1 Quarter
Other comprehensive income	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$1.35M	USD	1 Quarter
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Balance at the ending of period (in shares)	`CommonStockSharesOutstanding`	1.01B	shares	Point-in-time
Balance at the ending of period (in shares)	`CommonStockSharesOutstanding`	801.34M	shares	Point-in-time
Balance at the end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Balance at the end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.62B	USD	Point-in-time
Balance at the end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$978.36M	USD	Point-in-time
Balance at the end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.83B	USD	Point-in-time

Comprehensive Income 12 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-4.35M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$3.75M	USD	1 Quarter
Unrealized holding gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$685.00K	USD	1 Quarter
Unrealized holding gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$5.70M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-163.63M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-363.59M	USD	1 Quarter
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-1.31M	USD	1 Quarter
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-535.00K	USD	1 Quarter
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-362.28M	USD	1 Quarter
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-163.09M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.